<b>Exploring the Immunomodulatory Effects of Liposomal Daunorubicin on Jurkat Cells: A Study of Apoptosis and Gene Expression in Co-Cultured MDA-MB-231 Cells</b>

Background: Breast cancer represents a significant aspect of women’s health, constituting approximately 30% of cancers affecting them globally, with a mortality rate of around 15%. In the quest for healing, immunotherapy has emerged as a beacon of hope, employing our body’s innate defenses to confront cancer. Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) acts as a guardian, regulating immune responses, while COX-1’s influence on inflammation and invasion in cancer is modest yet notable. This study aims to explore the immunomodulatory effects of liposomal daunorubicin (LipDau) on Jurkat cells, evaluating the cancer cell fate through apoptosis and the expression of CTLA-4 and COX-1 genes in MDA-MB-231 cells as they co-exist with Jurkat cells. Methods: We assessed cell cytotoxicity in MDA-MB-231 cells under various treatments using the MTT assay. The apoptosis process was traced through flow cytometry, comparing controls, LipDau treatments, Jurkat cells, and activated Jurkat cells. The expression of CTLA-4 and COX-1 genes in MDA-MB-231 cells was measured through real-time PCR across similar treatments. Results: The application of LipDau, particularly in the presence of activated Jurkat cells, led to a significant decline in MDA-MB-231 cells, correlating with LipDau concentrations. Activated Jurkat cells demonstrated a lower IC50 than LipDau (21.5 and 31.1 μM, respectively). Notably, apoptosis rates rose sharply in MDA-MB-231 cells co-cultured with Jurkat cells at IC50 concentrations of LipDau, accompanied by decreased expression of CTLA-4 and COX-1 genes following treatment. Conclusion: Through the nurturing guidance of LipDau-activated Jurkat cells, a protective response emerged against tumor cells in MDA-MB-231, moderated by the CTLA-4 checkpoint and a suppression of inflammatory pathways via COX-1. These interactions facilitated the journey towards apoptosis and a halt in the relentless spread of metastatic breast cancer

Authors

Institutions

Publication Details

Journal
Pharmaceutical Sciences
Published
2025-05-26
DOI
https://doi.org/10.34172/ps.025.40918
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Exploring the Immunomodulatory Effects of Liposomal Daunorubicin on Jurkat Cells: A Study of Apoptosis and Gene Expression in Co-Cultured MDA-MB-231 Cells

Amir Arasteh, Mahsa M. Amoli, Mehdi Ebrahimi, Malik Kareem Shanan
Pharmaceutical Sciences
Nanoparticle-Based Drug Delivery
article

Exploring the Immunomodulatory Effects of Liposomal Daunorubicin on Jurkat Cells: A Study of Apoptosis and Gene Expression in Co-Cultured MDA-MB-231 Cells

Amir Arasteh, Mahsa M. Amoli, Mehdi Ebrahimi, Malik Kareem Shanan
article en

Abstract

Background: Breast cancer represents a significant aspect of women’s health, constituting approximately 30% of cancers affecting them globally, with a mortality rate of around 15%. In the quest for healing, immunotherapy has emerged as a beacon of hope, employing our body’s innate defenses to confront cancer. Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) acts as a guardian, regulating immune responses, while COX-1’s influence on inflammation and invasion in cancer is modest yet notable. This study aims to explore the immunomodulatory effects of liposomal daunorubicin (LipDau) on Jurkat cells, evaluating the cancer cell fate through apoptosis and the expression of CTLA-4 and COX-1 genes in MDA-MB-231 cells as they co-exist with Jurkat cells. Methods: We assessed cell cytotoxicity in MDA-MB-231 cells under various treatments using the MTT assay. The apoptosis process was traced through flow cytometry, comparing controls, LipDau treatments, Jurkat cells, and activated Jurkat cells. The expression of CTLA-4 and COX-1 genes in MDA-MB-231 cells was measured through real-time PCR across similar treatments. Results: The application of LipDau, particularly in the presence of activated Jurkat cells, led to a significant decline in MDA-MB-231 cells, correlating with LipDau concentrations. Activated Jurkat cells demonstrated a lower IC50 than LipDau (21.5 and 31.1 μM, respectively). Notably, apoptosis rates rose sharply in MDA-MB-231 cells co-cultured with Jurkat cells at IC50 concentrations of LipDau, accompanied by decreased expression of CTLA-4 and COX-1 genes following treatment. Conclusion: Through the nurturing guidance of LipDau-activated Jurkat cells, a protective response emerged against tumor cells in MDA-MB-231, moderated by the CTLA-4 checkpoint and a suppression of inflammatory pathways via COX-1. These interactions facilitated the journey towards apoptosis and a halt in the relentless spread of metastatic breast cancer

Pharmaceutical SciencesVol. 31(3)
Islamic Azad University, Science and Research Branch (IR), Islamic Azad University Rasht Branch (IR), Islamic Azad University of Varamin (IR), Tehran University of Medical Sciences (IR)
Openalex Percentile: Top 88%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.